Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2017 October;65(5) > Minerva Cardioangiologica 2017 October;65(5):531-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Cardioangiologica 2017 October;65(5):531-8

DOI: 10.23736/S0026-4725.17.04323-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Statins in primary prevention: impact on mortality. A meta-analysis study

José P. NUNES

Faculty of Medicine, University of Porto, Porto, Portugal


PDF


INTRODUCTION: An evaluation of the effects of statins on total mortality in the context of primary prevention was carried out, by means of the analysis of data taken from major clinical trials published in the literature.
EVIDENCE ACQUISITION: Published systematic reviews were used to identify relevant clinical trials, and data from the third Heart Outcomes Prevention Evaluation study were also used. Meta-analysis was carried out using overall mortality data.
EVIDENCE SYNTHESIS: A total of nine clinical trials were selected for further study, and in each of them patients had defined cardiovascular risk factors. Meta-analysis of the overall mortality results of the nine trials showed a significant reduction associated to statin therapy (odds ratio 0.886, 95% confidence limits 0.816-0.963), when compared to the control situation. At least one trial showed a numerical reduction of overall mortality with pravastatin, with atorvastatin and with rosuvastatin. Separate meta-analyses were carried out with clinical trials with each of these three drugs, yielding similar effects: pravastatin - odds ratio 0.852, 95% confidence limits 0.688-1.054; atorvastatin - odds ratio 0.853, 95% confidence limits 0.726-1.002; rosuvastatin - odds ratio 0.870, 95% confidence limits 0.749-1.010.
CONCLUSIONS: Statins used in primary prevention lead to a significant decrease in overall mortality. The effects of statins in primary prevention are limited to patients with defined cardiovascular risk factors.


KEY WORDS: Hydroxymethylglutaryl-CoA reductase inhibitors - Primary prevention - Mortality

top of page